



## Review

## Pros and cons of circumcision: an evidence-based overview

B. Friedman<sup>1</sup>, J. Khoury<sup>2,3</sup>, N. Petersiel<sup>2,3</sup>, T. Yahalomi<sup>2</sup>, M. Paul<sup>2,4</sup>, A. Neuberger<sup>2,3,4,\*</sup><sup>1</sup>) Department of Urology, Lady Davis Carmel Medical Center, Haifa, Israel<sup>2</sup>) Unit of Infectious Diseases, Rambam Medical Center, Haifa, Israel<sup>3</sup>) Internal Medicine B, Rambam Medical Center, Haifa, Israel<sup>4</sup>) Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel

## ARTICLE INFO

## Article history:

Available online 4 August 2016

Editor: D. Raoult

## Keywords:

Benefits  
Circumcision  
Effect  
HIV  
Impact  
Infections  
Male circumcision  
Sexually transmitted infections

## ABSTRACT

Based on three large randomized controlled trials (RCTs) conducted in Africa, it can clearly be stated that circumcision lowers the risk of infection with the human immunodeficiency virus (HIV) and some sexually transmitted infections (STIs) among males in settings of high HIV and STI endemicity. Similar effects on STI risk may exist for females, although this may result from an indirect effect of decreasing risk of infection among male partners. It is unknown whether circumcision prevents HIV acquisition in men who have sex with men (MSM), although there might be a protective effect for men who engage mainly in insertive anal intercourse. When the effects of adult circumcision on sexual function and satisfaction of men are examined, high-quality evidence strongly supports lack of harm. Whether circumcision alters sexual satisfaction of female partners is not known as fewer and smaller studies reported conflicting results. Circumcision rarely causes serious complications if practiced by trained practitioners, in a sterile setting, and with a proper follow-up. These conclusions are limited by the lack of high-quality data from areas outside of Africa. RCTs have not been conducted to assess the effects of circumcising infants or MSM. Circumcision has well-proven benefits for people residing in areas with high prevalence of STIs, including HIV, and is not unethical for those who choose to be circumcised or have their children circumcised on religious, social, or cultural grounds. For many others, a definite pro or con recommendation, based on a risk-benefit ratio, cannot be made. **B. Friedman, CMI 2016;22:768**

© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

## Introduction

Few procedures generate as much controversy as male circumcision. While religious and social factors strongly influence the decision of many adults and parents about circumcision, others seek to understand in what ways, medically speaking, this procedure can bring benefits or cause harm. While reviewing the literature for this review we have made two observations: first, the abundance of very low-quality research, some of which is clearly biased unreservedly for or against circumcision; second, the bulk of trials and systematic reviews concentrate on one aspect of possible benefits or harms, but do not provide a general overview [1]. Thus, we have tried to filter out bad science, and provide a balanced

discussion of the pros and cons of circumcision for those who have to make a very personal decision.

## Methods

We searched PubMed and the Cochrane Library for the term 'circumcision', filtering in PubMed for clinical trials and systematic reviews. We addressed primarily systematic reviews of randomized controlled trials (RCTs). Where unavailable, we searched for RCTs, and when RCTs were unavailable or insufficient we included observational studies in the literature review. We rated the quality of the evidence as very low, low, moderate, or high. We based the rating primarily on the study design (high quality for RCTs and low quality for observational studies) and then downgraded or upgraded according to the internal validity of each study, following the GRADE recommendations [2]. We accepted the quality rating from systematic reviews using the GRADE system and risk of bias assessment from other systematic reviews. We used the

\* Corresponding author. A. Neuberger, Rambam Medical Center, Unit of Infectious Diseases, 8 Haalya Hashnya St., Haifa, 3109601, Israel.

E-mail address: [a\\_neuberger@rambam.health.gov.il](mailto:a_neuberger@rambam.health.gov.il) (A. Neuberger).

terminology ‘affected’ for high-quality evidence, ‘probably affected’ for moderate-quality evidence, ‘may be affected’ for low-quality evidence, and ‘effect not known’ for very low-quality or no evidence [3].

## Circumcision and the risk of HIV acquisition

### Heterosexual men

The inner surface of the foreskin contains Langerhans cells with human immunodeficiency virus (HIV) receptors, which explains the biological rationale for using male circumcision to decrease rates of HIV acquisition among men [4]. Early non-randomized studies attempting to assess the effects of circumcision on HIV could not control for religion and tradition as confounding factors. Three major RCTs comparing immediate and delayed (21–24 months) circumcision, and assessing HIV acquisition in the interval, were conducted in South-Africa, Kenya, and Uganda in the 2000s. All were stopped early when male circumcision was shown to decrease the rates of HIV acquisition in planned interim-analysis [5–7] (Table 1). A Cochrane review of these RCTs, which included a total of 11 500 men, showed that circumcision reduced HIV acquisition with an incidence risk ratio (IRR) of 0.46 (95% CI 0.34–0.62) at the end of follow-up. The number needed to treat (NNT) at 21–24 months was 56 (95% CI 41–90). Circumcision prevented 17 HIV infections (95% CI 11–24) over 2 years per 1000 men, with a control event rate of 2.5% translating to a population yearly incidence of HIV acquisition of 1.25% [8]. The quality of the evidence was moderate to high, downgraded for unreliable randomization methods in two of the trials and early discontinuation in all three trials (although discontinuation rules were defined in all three).

The public health implications of male circumcision have not been studied adequately, as all RCTs assessed the effects of the intervention on individuals rather than on populations. A few mathematical models have been proposed aiming at estimating the potential impact of increased circumcision coverage on the incidence of HIV in Africa. A dynamical simulation model, for example, suggested that full coverage of circumcision could avert 0.3 (0.1–0.5) million deaths in the first 10 years and a further 2.7 (1.5–5.3) million in the next 10 years, in sub-Saharan Africa [9]. However, by definition, models can never account for all additional factors that can influence the impact of a specific intervention on disease incidence [10]. Increasing rates of antiretroviral coverage make impossible long-term assessment of the procedure itself, and the effect of circumcision on sexual risk-taking is unknown. In the three RCTs described above, circumcised males practiced riskier sex behaviours, leading to concerns about disinhibition and higher transmission rates of HIV. Other observational studies from Africa

showed mixed results regarding the possibility of disinhibition following circumcision. Recently, a cohort study from Uganda found that, while the circumcision programme attracts more sexually active males, it does not alter their sexual behaviour [11–13].

Evidence outside of Africa comes mostly from observational studies. Such studies were conducted in the USA and Israel, where circumcision rates are high and HIV burden is relatively low, and similarly showed an inverse association between circumcision and HIV acquisition [14,15]. A systematic review of studies conducted in India included 13 observational studies, showing that circumcision may reduce HIV acquisition by approximately 40% (OR 0.66; 95% CI 0.53–0.83) [16]. As circumcision in India is almost exclusively practiced by Muslims, bias is likely (low-quality evidence).

Following the publication of the RCTs from Africa, the Center for Disease Control and Prevention (CDC) announced in 2007 that there is ‘sufficient evidence to inform heterosexually active males about the significant, albeit partial, efficacy of medical circumcision in reducing the risk of HIV infection’ [17]. Similarly, the WHO/UNAIDS recommends male circumcision as an efficacious intervention for HIV prevention in countries with high HIV incidence and low male circumcision prevalence [18].

### Women

As male circumcision reduces the incidence of HIV among men, it may indirectly reduce the risk of exposure to women. Whether circumcision can directly prevent the acquisition of HIV by female partners of HIV-infected men is uncertain. Only one RCT, conducted in Uganda in 2009, addressed this issue and was discontinued early because of futility [19]. In this trial 922 discordant couples were enrolled and randomized either to circumcision or control (delayed circumcision for 24 months). Surprisingly, there was a small increase in the risk of HIV acquisition among women in the intervention group, mainly because of early resumption of sexual activity before wound healing, and an increase in the viral load shortly after circumcision (high-level evidence). A systematic review summarizing this RCT and a few longitudinal observational studies showed that male circumcision probably does not reduce the risk for HIV among women (relative risk 0.80, 95% CI 0.53–1.36) [20].

### Men who have sex with men (MSM)

To the best of our knowledge, no RCT assessed the impact of circumcision on the risk of HIV acquisition among MSM. A Cochrane systematic review published in 2011 included 20 observational studies in high- and middle-income countries with a total of 65 784 participants. The meta-analysis showed that circumcision

**Table 1**  
Randomized controlled trials of immediate vs. delayed surgical circumcision in Africa

	Auvert 2005 [5]	Bailey 2007 [6]	Gray 2007 [7]
Location	Orange Farm, South Africa	Kisumu, Kenya	Rakai, Uganda
Study years	2002–2005	2002–2005	2002–2006
Age range (years)	18–24	18–24	15–49
N patients	3274	2784	4996
Duration of follow-up	21 months	24 months	24 months
Risk of bias <sup>a</sup>			
Selection bias <sup>b</sup>	High risk	Unclear	High risk
Other	None	None	None

<sup>a</sup> All trials stopped early based on pre-defined stopping rules. As the primary outcome (HIV acquisition) was objective, blinding was deemed less relevant and is not addressed.

<sup>b</sup> Based on the highest risk of random sequence generation and allocation concealment.

may reduce HIV acquisition among MSM reporting an insertive anal role (seven studies), but might not have an effect among MSM practicing a receptive role (three studies), low-quality evidence [21]. Similar results were reported in another systematic review, highlighting that a protective effect was demonstrated only in studies conducted before the highly active antiretroviral therapy era [22]. Recently, an observational study of the risk of HIV acquisition conducted among MSM in China, involving 1155 men, showed that circumcised MSM were less likely to acquire HIV (aOR, 0.46; 95% CI 0.24–0.89). Again, this protective effect was most pronounced among MSM who predominantly practiced insertive anal intercourse [23].

### Adult circumcision and sexually transmitted infections

To provide an overview of the evidence on the effect of circumcision on the risk of acquisition of various sexually transmitted infections (STIs), we will separate infections into those in which incidence is decreased, those in which incidence is possibly decreased, and those in which incidence is unaffected by circumcision.

#### Heterosexual men

STIs whose incidence is decreased or likely to be decreased following circumcision include:

- Human papilloma virus (HPV), high-quality evidence: large RCTs of immediate versus deferred circumcision, all of which were performed in Africa, included a total of 3921 and 3815 men in the intervention and control arms, respectively. These trials clearly demonstrate that circumcision decreases HPV infection rates among HIV-negative heterosexual men. Overall infection rates were 14.8–18% in the intervention group and 23.3–27.8% in the control group [24–27]. Among HIV-positive men included in an RCT performed in Uganda, circumcision decreased the risk of high-risk multiple HPV genotype infections (RR 0.40, 95% CI 0.19–0.84), control event rate 24.7% [28].
- Mycoplasma (moderate-quality evidence): in one RCT from Kenya, which included 2784 men, the prevalence of *Mycoplasma genitalium* was 13.4% among uncircumcised men versus 8.2% among circumcised men. After adjustment for other risk factors for infection, being circumcised nearly halved the odds of *Mycoplasma genitalium* infection (aOR 0.54; 95% CI 0.29–0.99) [29].
- Genital ulcer disease (GUD): the clinical syndrome of GUD is caused mainly by STIs, and its incidence is assessed as a general estimate of STI incidence when specific microbiologic diagnoses are not available. Two large RCTs, which included 8315 participants, showed that GUD incidence was halved among circumcised men, with a risk ratio of 0.51–0.52 [30]. Similarly, a prospective observational study of 746 men showed that an uncircumcised status was an independent risk factor for GUD (hazard rate ratio = 2.5) [31].

STIs whose incidence is possibly decreased by circumcision:

- Syphilis: one large RCT from Uganda, which included 5534 men, showed no significant difference between circumcised and uncircumcised men in new acquisition of syphilis (adjusted hazard ratio 1.10, 95% CI 0.75–1.65,  $p = 0.44$ ) [24]. On the other hand, another RCT, performed on 4761 males in Kenya and Uganda, showed that circumcision was associated with a 42% reduction in the incidence of syphilis (adjusted hazard ratio 0.58, 95% CI 0.37–0.91). In a subgroup analysis among HIV-infected men, a 62% reduction in the incidence of syphilis was noted (0.38,

0.18–0.81), whereas a nonsignificant reduction in the incidence of syphilis was observed among men without HIV (0.64, 0.36–1.11) [31].

- Herpes Simplex Virus (HSV): RCTs from Uganda [24] and South Africa [32] showed a significant reduction in HSV infection rates after circumcision. Two other trials conducted in Kenya failed to show such a reduction [30–33]. The discrepancy between these trials was attributed to lack of specificity of the assay used in some trials, different prevalence of HSV at baseline, different age groups, and different numbers of sexual partners.

Finally, STIs whose incidence is probably not affected by circumcision include:

- Gonorrhoea: one RCT [34] and one observational study [35], both performed in Africa, did not show a risk reduction of gonorrhoeal infection after circumcision.
- *Chlamydia*: one RCT did not show a relationship between circumcision status and *Chlamydia* infection [34].

The evidence summarized above derives mostly from an analysis of secondary outcomes in the circumcision RCTs conducted in Africa, performed to assess its effect on HIV acquisition. The effects of circumcision on STIs in non-African countries have not been studied rigorously. Based on observational studies conducted in the USA, it is likely that circumcision both prevents HPV and increases the likelihood for clearing existing HPV infections [36,37]. Data on HSV are conflicting as a cohort study conducted in Australia showed a protective effect of circumcision, whereas trials in America and India failed to demonstrate such an effect [38–40]. Studies conducted in the USA, India, and Austria demonstrated conflicting results with regard to the effect of circumcision on the incidence of HSV and syphilis [38–41].

#### Female partners

STIs whose incidence is decreased or likely to be decreased:

- HPV: based on three RCTs conducted in Uganda, there is strong evidence that male circumcision decreases HPV infection rates in female partners of circumcised HIV-negative males [42,43], but does not affect HPV transmission among couples when the men are HIV positive [44]. Outside of Africa, a meta-analysis on 1913 couples included in case-control studies, showed that circumcision is associated with a lower risk of cervical cancer among monogamous female partners of men with multiple sexual partners (aOR 0.42, 95% CI 0.23–0.79) [45].

STIs whose incidence is possibly decreased by circumcision:

- GUD and bacterial vaginosis: based on a single RCT, the risk for GUD, bacterial vaginosis, and trichomonas infection may be reduced in female partners of circumcised males [46]. Circumcision was not associated with a lower risk for bacterial vaginosis in one retrospective study conducted in the USA [47].
- *Chlamydia trachomatis*: in a multinational retrospective study, circumcision was associated with a lower risk for *Chlamydia trachomatis* infection in female sexual partners of circumcised males [48].

STIs whose incidence is probably not affected by circumcision:

- HSV and genital mycoplasma: the risk of HSV and genital mycoplasma infections is probably not reduced in females whose sexual partners have been circumcised [49,50].

### Men who have sex with men

To the best of our knowledge, no RCT has assessed the effect of circumcision on the risk of STIs among MSM. In several observational trials no association has been found between male circumcision and STIs [51–54]. The STIs assessed included HSV-2, syphilis, urethral gonorrhoea, and urethral *Chlamydia* infection. One study reported a significant, protective effect of circumcision on the risk of syphilis acquisition, and no association for other STIs [55], while another reported no association for most STIs, but a significantly greater risk of acquiring non-chlamydial non-gonococcal urethritis [56].

### Effects of circumcision on sexual function and satisfaction

#### Men

Two of the RCTs conducted in Africa primarily to assess the effects of circumcision on HIV, also analysed outcomes related to sexual function and satisfaction. In the trial conducted in Uganda, decreased sexual satisfaction or sexual dysfunction were reported equally by <2% of participants in both study arms [57]. In the trial from Kenya, circumcision similarly did not affect sexual dysfunction. Men in the intervention group reported increased penile sensitivity and enhanced ease of reaching orgasm, with 99.5% of circumcised participants reporting that they were ‘very satisfied’ with the outcome [11,58,59]. Participants in several large non-randomized trials conducted in Africa similarly reported that they

had either equal or improved sexual satisfaction following circumcision [60,61].

Evidence in middle- or high-income countries is mostly derived from low-quality observational trials, the majority of which did not account sufficiently for confounders. Such studies were conducted in China [62], Taiwan [63], Korea [64], several European countries [65,66], Australia [67], and the USA. Most studies reported either no harm or increased sexual satisfaction, while fewer studies reported some degree of sexual dysfunction. In one relatively large observational trial conducted among MSM in Australia, sexual dysfunction or decreased sexual satisfactions were similar among circumcised and non-circumcised participants [67].

#### Women

Few studies examined women's preferences regarding the status of partner circumcision. In the trial conducted in Uganda, nearly all women (97.1%) reported either no change or improved sexual satisfaction after their partners were circumcised [68]. The vast majority of women partners of male participants in the trial from Kenya reported that they were very satisfied (92%) or somewhat satisfied (5%) with the outcome of circumcision [59]. Other large observational trials conducted in Africa reported similar results: in Malawi, women were more likely to report greater sexual pleasure with a circumcised partner [61], and similar results were observed in Zambia [60]. The only relatively large study conducted in a high-income country reported that circumcision might decrease sexual satisfaction among female partners. This analysis is limited by a

**Table 2**

Effect of circumcision on the risk of acquiring human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs) in randomized controlled trials (RCTs)

Pathogen or syndrome	Countries	Effect of circumcision	Comments
HIV			
HIV among heterosexual men	South Africa [5] Kenya [6] Uganda [7]	RR 0.4 (0.24–0.68) RR 0.47 (0.28–0.78) RR 0.43 (0.24–0.75)	Relative risk similar in all three large RCTs
HIV among females	Uganda [19]	HR 1.49 (0.62–3.57)	Circumcision of HIV-infected males did not reduce HIV-transmission to female partners
HIV among MSM	South Africa [21] - Insertive role - Receptive role	OR 0.27 (0.17–0.44) OR 1.2 (0.63–2.29)	Circumcision prevented HIV only in MSM practicing mainly insertive anal sex
STIs among heterosexual men			
HPV	Uganda [24] Uganda [25] Uganda [28] South Africa [26] Kenya [27]	aRR 0.65 (0.46–0.90) RR 0.67 (0.51–0.89) RR 0.4 (0.19–0.84) PRR 0.66 (0.51–0.86) RR 0.34 (0.13–0.86)	Circumcision reduced HPV infection in both HIV-positive [22] and HIV-negative men
Mycoplasma	Kenya [29]	OR 0.54 (0.29–0.99)	
Genital ulcer disease (GUD)	Kenya [24] Uganda [31] - HSV-negative - HSV-positive	RR 0.52 (0.37–0.73) PRR 0.51 (0.43–0.74) PRR 0.66 (0.51–0.69)	
Syphilis	Uganda [24] Uganda [31]	aHR 1.1 (0.75–1.65) RR 0.58 (0.37–0.91)	In a subgroup analysis of the Ugandan trial, circumcision was protective against syphilis among HIV-positive, but not among HIV-negative men
HSV	Uganda [24] South Africa [32] Kenya [30] Kenya [33]	aHR 0.72 (0.56–0.92) IRR 0.45 (0.24–0.82) RR 0.94 (0.70–1.25) HR 0.88 (0.77–1.10)	In some, but not all trials there was a reduction in HSV incidence. Trials differed in prevalence of HSV at baseline, age groups, number of sexual partners, and assays used
Gonorrhoea	Kenya [28] South Africa [29]	IRR 0.95 (0.68–1.34) OR 0.97 (0.71–1.32)	No effect
Chlamydia	Kenya [34] South Africa [35]	IRR 0.87 (0.65–1.16) OR 0.58 (0.33–1.03)	No effect
STIs among females			
HPV	Uganda [42] Uganda [43] Uganda [44]	RR 0.72 (0.60–0.85) RR 0.66 (0.50–0.87) RR 1.07 (0.86–1.32)	Circumcision reduced HPV infection rates of female partners of HIV negative men [36,37], but not of HIV positive men [38]
Genital ulcer disease	Uganda [46]	RR 0.78 (0.63–0.97)	
Mycoplasma	Uganda [50]	PRR 1.0 (0.48–2.12)	

aRR, adjusted risk reduction; HPV, human papilloma virus; HSV, herpes simplex virus; IRR, incidence rate ratio; MSM, men who have sex with men; PRR, prevalence risk ratio.

cross-sectional design, and a low number of circumcised participants (125 out of 2345 participants) [69].

## Complications of the circumcision procedure

### *Surgical circumcision*

Conventional circumcision by surgical removal of the foreskin is the standard procedure used in most circumcision programmes. Circumcision may result in early (intraoperative) or late (post-operative) complications [70–72]. Early complications tend to be minor and treatable: pain, bleeding, swelling, or inadequate skin removal [70,73]. Serious complications, such as amputation of the glans penis, occur only rarely [74,75]. Late complications may include pain, wound infection, oedema, and urinary retention, meatal ulcer, meatal stenosis, foreskin adhesions, fistulas, and loss of penile sensitivity [76]. Rates of reported complications vary greatly between studies, as these rates are affected by the setting of the surgical procedure and data collection methods [77,78].

Complication rates correlate with age, occurring least often in neonates and infants. In a systematic review the median frequency of any serious adverse event following neonatal or infantile circumcision performed by medically trained providers was 1.5% (range 0–16%) and 0% (range 0–2%), respectively. In children aged 1 year old or older, the median frequency of any or serious adverse event was 6% (range 2–14%), and 0% (range 0–3%), respectively [79]. The simpler nature of the procedure among neonates – no need for suturing, and better healing – was hypothesized to underlie the lower rate of complications in this age group. In high- and middle-income countries, but not in Africa, adverse events were observed most commonly among boys circumcised for medical, rather than religious or cultural reasons [80–82]. In a study that included boys circumcised mainly for phimosis in the UK, the frequency of any adverse events was 6.4%, and 2.8% required re-admission to hospital [80]; similar frequencies of readmissions were reported in a Danish study [81].

In middle- to high-income countries (Iran and Israel), some case-control studies found that UTIs were more likely to occur following circumcision by a traditional, rather than a medical provider [83–86]. In this context it should be noted that the lifelong risk of UTI is reduced by the procedure [87]. Data from African countries clearly show that the rate of complications is higher when conducted in a traditional setting [11,76,88–90]. A systematic review of complications after traditional male circumcision in South African found rates of 35% to 48%, and a mortality rate of 0.2%. Poor postoperative care by traditional circumcisers is likely to contribute to increased complication rates [89,90].

### *Non-surgical circumcision*

In recent years, there has been an increase among adults in the use of circumcision devices that do not require suturing and haemostasis. A systematic review summarizing eight RCTs, including 3314 patients, compared the safety and efficacy of conventional versus device-assisted circumcision [91]. A lower complication rate was observed in the device group in comparison with the conventional technique group (RR 0.54, 95% CI 0.39–0.74). This difference was largely driven by lower bleeding and higher healing rates. Nevertheless, the expertise of the provider may be much more influential on the incidence of complications than the technique used [79,90].

## Conclusions

The effects of circumcision are still largely debated, and conflicting conclusions have been drawn from existing data.

It can be clearly stated that adult circumcision decreases the rate of HIV acquisition among men in settings with a high incidence of HIV and therefore indirectly reduces risk of exposure to women (Table 2). We do not know whether there is a direct effect of male circumcision on women's risk for HIV. There may be a transient increase in HIV acquisition risk if sexual intercourse occurs immediately after the procedure, before wound healing. It is also uncertain whether circumcision prevents HIV acquisition in MSM, although there might be a protective effect for men who mainly engage in insertive anal intercourse. The RCTs conducted in Africa provide ample evidence of the effect of circumcision on the prevention of several, albeit not all, STIs among men. Evidence among female sexual partners is of lower quality, but also seems to show a beneficial effect for some STIs. Evidence among MSM comes from observational trials, which may be inadvertently biased, so that no definite conclusions can be drawn. Severe adverse events after adult and infant circumcision are rare.

All these beneficial effects of circumcision are relevant for high HIV- and STI-endemicity settings. Additional proven benefits of circumcision such as the prevention of balanitis and phimosis were beyond the scope of this review. Whether circumcision carries benefit outside of Africa is unknown. We do not know the effects of circumcision following infant or child circumcision performed as part of religious or social ceremonies. In this setting the relevant outcomes might be UTIs in infants and life-long STI acquisition. In addition, the scope of this review does not allow for a full discussion of the epidemiological impact of a circumcision policy in high-income countries, and in Africa. Such impact was estimated to be significant even outside of Africa [92].

Deciding whether to perform the procedure is easier for people residing in areas with high prevalence of STIs, including HIV, and for those who choose to be circumcised or have their children circumcised on religious, social, or cultural grounds. For many others, a definite pro or con recommendation, based on a risk-benefit ratio, cannot be made.

## Transparency declaration

There was no funding for this study. All authors report no conflicts of interests.

## References

- [1] Morris BJ, Hankins CA, Tobian AA, Krieger JN, Klausner JD. Does male circumcision protect against sexually transmitted infections? Arguments and meta-analyses to the contrary fail to withstand scrutiny. *ISRN Urol* 2014;2014:684706.
- [2] Guyatt G, Oxman A, Vist G. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336(7650):924–6.
- [3] Glenton C, Santesso N, Rosenbaum S, Nilsen ES, Rader T, Ciapponi A, et al. Presenting the results of cochrane systematic reviews to a consumer audience: a qualitative study. *Med Decis Mak* 2010;30:566–77.
- [4] Szabo R, Short RV, Fauci A, Halperin D, Bailey R, Cook L, et al. How does male circumcision protect against HIV infection? *BMJ* 2000;320:1592–4.
- [5] Auvvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. *PLoS Med* 2005;2:e298.
- [6] Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. *Lancet (London, England)* 2007;369:643–56.
- [7] Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. *Lancet* 2007;369:657–66.
- [8] Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. *Cochrane Database Syst Rev* 2009; CD003362.

- [9] Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, Hargrove J, et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. *PLoS Med* 2006;3(7):e262.
- [10] Neuberger A, Paul M, Nizar A, Raoult D. Modelling in infectious diseases: between haphazard and hazard. *Clin Microbiol Infect* 2013;19(11):993–8.
- [11] Gray RH, Kigozi G, Kong X, Ssemplijia V, Makumbi F, Watty S, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a post-trial follow up study in Rakai Uganda. *AIDS* 2012;26(5):609–15.
- [12] Kibira SPS, Sandøy IF, Daniel M, Atuyambe LM, Makumbi FE. A comparison of sexual risk behaviours and HIV seroprevalence among circumcised and uncircumcised men before and after implementation of the safe male circumcision programme in Uganda. *BMC Public Health* 2016;16:7.
- [13] Kagaayi J, Kong X, Kigozi G, Ssekubugu R, Kigozi G, Nalugoda F, et al. Self-selection of male circumcision clients and behaviors following circumcision in a service program in Rakai, Uganda. *AIDS* 2016;30(13):2125–9.
- [14] Warner L, Ghanem KG, Newman DR, Macaluso M, Sullivan PS, Erbeding EJ. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. *J Infect Dis* 2009;199:59–65.
- [15] Chemtob D, Op de Coul E, van Sighem A, Mor Z, Cazein F, Semaille C. Impact of male circumcision among heterosexual HIV cases: comparisons between three low HIV prevalence countries. *Isr J Health Policy Res* 2015;4:36.
- [16] Arora P, Nagelkerke NJD, Jha P. A systematic review and meta-analysis of risk factors for sexual transmission of HIV in India. *PLoS One* 2012;7:e44094.
- [17] Smith DK, Taylor A, Kilmarx PH, Sullivan P, Warner L, Kamb M, et al. Male circumcision in the United States for the prevention of HIV infection and other adverse health outcomes: report from a CDC consultation. *Public Health Rep* 2010;125:72–82.
- [18] **New Data on Male Circumcision and HIV Prevention: Policy and Programme Implications Conclusions and Recommendations.** WHO/UNAIDS technical consultation on male circumcision and HIV prevention: research implications for policy and programming, Montreux, 6–8 March 2007 Conclusions and recommendations.
- [19] Wawer MJ, Makumbi F, Kigozi G, Serwadda D, Watya S, Nalugoda F, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. *Lancet* 2009;374:229–37.
- [20] Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. *Lancet Infect Dis* 2009;9:669–77.
- [21] Wiyongse CS, Kongnyuy EJ, Shey M, Muula AS, Navti OB, Akl EA, et al. Male circumcision for prevention of homosexual acquisition of HIV in men. *Cochrane Database Syst Rev* 2011:CD007496.
- [22] Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. *JAMA* 2008;300:1674–84.
- [23] Qian H-Z, Ruan Y, Liu Y, Milam DF, Spiegel HML, Yin L, et al. Lower HIV risk among circumcised men who have sex with men in China: Interaction with anal sex role in a cross-sectional study. *J Acquir Immune Defic Syndr* 2016;71:444–51.
- [24] Tobian AAR, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. *N Engl J Med* 2009;360:1298–309.
- [25] Gray RH, Serwadda D, Kong X, Makumbi F, Kigozi G, Gravitt PE, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. *J Infect Dis* 2010;201:1455–62.
- [26] Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. *J Infect Dis* 2009;199:14–9.
- [27] Senkomago V, Backes DM, Hudgens MG, Poole C, Agot K, Moses S, et al. Acquisition and persistence of human papillomavirus 16 (HPV-16) and HPV-18 among men with high-HPV viral load infections in a circumcision trial in Kisumu, Kenya. *J Infect Dis* 2015;211:811–20.
- [28] Serwadda D, Wawer MJ, Makumbi F, Kong X, Kigozi G, Gravitt P, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. *J Infect Dis* 2010;201:1463–9.
- [29] Mehta SD, Gaydos C, Maclean I, Odoyo-June E, Moses S, Agunda L, et al. The effect of medical male circumcision on urogenital mycoplasma genitalium among men in Kisumu, Kenya. *Sex Transm Dis* 2012;39:276–80.
- [30] Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. *AIDS* 2012;26:1141–9.
- [31] Gray RH, Serwadda D, Tobian AAR, Chen MZ, Makumbi F, Suntuoke T, et al. Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: analyses from the Rakai trials. *PLoS Med* 2009;6:e1000187.
- [32] Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. *J Infect Dis* 2009;199:958–64.
- [33] Mehta SD, Moses S, Agot K, Maclean I, Odoyo-June E, Li H, et al. Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. *J Infect Dis* 2013;208:1869–76.
- [34] Mehta SD, Moses S, Agot K, Parker C, Ndinya-Achola JO, Maclean I, et al. Adult male circumcision does not reduce the risk of incident *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, or *Trichomonas vaginalis* infection: results from a randomized, controlled trial in Kenya. *J Infect Dis* 2009;200:370–8.
- [35] Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and *Neisseria gonorrhoeae*, *Chlamydia trachomatis* and *Trichomonas vaginalis*: observations after a randomised controlled trial for HIV prevention. *Sex Transm Infect* 2009;85:116–20.
- [36] Nielson CM, Schiaffino MK, Dunne EF, Salemi JL, Giuliano AR. Associations between male anogenital human papillomavirus infection and circumcision by anatomic site sampled and lifetime number of female sex partners. *J Infect Dis* 2009;199:7–13.
- [37] Lu B, Wu Y, Nielson CM, Flores R, Abrahamsen M, Papenfuss M, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. *J Infect Dis* 2009;199:362–71.
- [38] Parker SW, Stewart AJ, Wren MN, Gollow MM, Stratton JA. Circumcision and sexually transmissible disease. *Med J Aust* 1983;2:288–90.
- [39] Cook LS, Koutsky LA, Holmes KK. Circumcision and sexually transmitted diseases. *Am J Public Health* 1994;84:197–201.
- [40] Reynolds SJ, Shepherd ME, Risbud AR, Gangakhedkar RR, Brookmeyer RS, Divekar AD, et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. *Lancet* 2004;363:1039–40.
- [41] Diseker RA, Peterman TA, Kamb ML, Kent C, Zenilman JM, Douglas JM, et al. Circumcision and STD in the United States: cross sectional and cohort analyses. *Sex Transm Infect* 2000;76:474–9.
- [42] Wawer MJ, Tobian AAR, Kigozi G, Kong X, Gravitt PE, Serwadda D, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. *Lancet (London, England)* 2011;377:209–18.
- [43] Davis M-A, Gray RH, Grabowski MK, Serwadda D, Kigozi G, Gravitt PE, et al. Male circumcision decreases high-risk human papillomavirus viral load in female partners: a randomized trial in Rakai, Uganda. *Int J Cancer* 2013;133:1247–52.
- [44] Tobian AAR, Kong X, Wawer MJ, Kigozi G, Gravitt PE, Serwadda D, et al. Circumcision of HIV-infected men and transmission of human papillomavirus to female partners: analyses of data from a randomised trial in Rakai, Uganda. *Lancet Infect Dis* 2011;11:604–12.
- [45] Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, de Sanjose S, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. *N Engl J Med* 2002;346:1105–12.
- [46] Gray RH, Kigozi G, Serwadda D, Makumbi F, Nalugoda F, Watya S, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. *Am J Obstet Gynecol* 2009;200:42.e1–7.
- [47] Zenilman JM, Friesia A, Berger B, McCormack WM. Bacterial vaginosis is not associated with circumcision status of the current male partner. *Sex Transm Infect* 1999;75:347–8.
- [48] Castellsagué X, Peeling RW, Franceschi S, de Sanjosé S, Smith JS, Albero G, et al. Chlamydia trachomatis infection in female partners of circumcised and uncircumcised adult men. *Am J Epidemiol* 2005;162:907–16.
- [49] Brankin AE, Tobian AAR, Laeyendecker O, Suntuoke TR, Kizza A, Mpoza B, et al. Aetiology of genital ulcer disease in female partners of male participants in a circumcision trial in Uganda. *Int J STD AIDS* 2009;20:650–1.
- [50] Tobian AAR, Gaydos C, Gray RH, Kigozi G, Serwadda D, Quinn N, et al. Male circumcision and *Mycoplasma genitalium* infection in female partners: a randomized trial in Rakai, Uganda. *Sex Transm Infect* 2014;90:150–4.
- [51] Mor Z, Kent CK, Kohn RP, Klausner JD. Declining rates in male circumcision amidst increasing evidence of its public health benefit. *PLoS One* 2007;2:e861.
- [52] Millett GA, Ding H, Lauby J, Flores S, Stueve A, Bingham T, et al. Circumcision status and HIV infection among Black and Latino men who have sex with men in 3 US cities. *J Acquir Immune Defic Syndr* 2007;46:643–50.
- [53] Jameson DR, Celum CL, Manhart L, Menza TW, Golden MR. The association between lack of circumcision and HIV, HSV-2, and other sexually transmitted infections among men who have sex with men. *Sex Transm Dis* 2010;37:147–52.
- [54] Jozkowski K, Rosenberger JG, Schick V, Herbenick D, Novak DS, Reece M. Relations between circumcision status, sexually transmitted infection history, and HIV serostatus among a national sample of men who have sex with men in the United States. *AIDS Patient Care STDS* 2010;24:465–70.
- [55] Kreiss JK, Hopkins SG. The association between circumcision status and human immunodeficiency virus infection among homosexual men. *J Infect Dis* 1993;168:1404–8.
- [56] Lafferty WE, Hughes JP, Handsfield HH. Sexually transmitted diseases in men who have sex with men. Acquisition of gonorrhoea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. *Sex Transm Dis* 1997;24:272–8.
- [57] Kigozi G, Watya S, Polis CB, Buwembo D, Kiggundu V, Wawer MJ, et al. The effect of male circumcision on sexual satisfaction and function, results from a randomized trial of male circumcision for human immunodeficiency virus prevention, Rakai, Uganda. *BJU Int* 2008;101:65–70.

- [58] Krieger JN, Mehta SD, Bailey RC, Agot K, Ndinya-Achola JO, Parker C, et al. Adult male circumcision: effects on sexual function and sexual satisfaction in Kisumu, Kenya. *J Sex Med* 2008;5:2610–22.
- [59] Krieger JN, Bailey RC, Opeya JC, Ayieko BO, Opiyo FA, Omondi D, et al. Adult male circumcision outcomes: experience in a developing country setting. *Urol Int* 2007;78:235–40.
- [60] Zulu R, Jones D, Chitalu N, Cook R, Weiss S. Sexual satisfaction, performance, and partner response following voluntary medical male circumcision in Zambia: the spear and shield project. *Glob Heal Sci Pract* 2015;3:606–18.
- [61] Shacham E, Godlonton S, Thornton RL. Perceptions of male circumcision among married couples in rural Malawi. *J Int Assoc Provid AIDS Care* n.d.;13:443–449.
- [62] Gao J, Xu C, Zhang J, Liang C, Su P, Peng Z, et al. Effects of adult male circumcision on premature ejaculation: results from a prospective study in China. *Biomed Res Int* 2015;2015:417846.
- [63] Yang M-H, Tsao C-W, Wu S-T, Chuang F-P, Meng E, Tang S-H, et al. The effect of circumcision on young adult sexual function. *Kaohsiung J Med Sci* 2014;30:305–9.
- [64] Kim D, Pang M-G. The effect of male circumcision on sexuality. *BJU Int* 2007;99:619–22.
- [65] Senel FM, Demirelli M, Misirlioglu F, Sezgin T. Adult male circumcision performed with plastic clamp technique in Turkey: results and long-term effects on sexual function. *Urol J* 2012;9:700–5.
- [66] Waldinger MD, McIntosh J, Schweitzer DH. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. *J Sex Med* 2009;6:2888–95.
- [67] Mao L, Templeton DJ, Crawford J, Imrie J, Prestage GP, Grulich AE, et al. Does circumcision make a difference to the sexual experience of gay men? Findings from the Health in Men (HIM) cohort. *J Sex Med* 2008;5:2557–61.
- [68] Kigozi G, Lukabwe I, Kagaayi J, Wawer MJ, Nantume B, Kigozi G, et al. Sexual satisfaction of women partners of circumcised men in a randomized trial of male circumcision in Rakai, Uganda. *BJU Int* 2009;104:1698–701.
- [69] Frisch M, Lindholm M, Grønbaek M. Male circumcision and sexual function in men and women: a survey-based, cross-sectional study in Denmark. *Int J Epidemiol* 2011;40:1367–81.
- [70] Lerman SE, Liao JC. Neonatal circumcision. *Pediatr Clin North Am* 2001;48:1539–57.
- [71] Shenfeld OZ, Ad-El D. [Penile reconstruction after complete glans amputation during ritual circumcision]. *Harefuah* 2000;139:352–4. 407.
- [72] Strimling BS. Partial amputation of glans penis during Mogen clamp circumcision. *Pediatrics* 1996;97:906–7.
- [73] Williams N, Kapila L. Complications of circumcision. *Br J Surg* 1993;80:1231–6.
- [74] El Bcheraoui C, Zhang X, Cooper CS, Rose CE, Kilmarx PH, Chen RT. Rates of adverse events associated with male circumcision in US medical settings, 2001 to 2010. *JAMA Pediatr* 2014;168:625–34.
- [75] Cathcart P, Nuttall M, van der Meulen J, Emberton M, Kenny SE. Trends in paediatric circumcision and its complications in England between 1997 and 2003. *Br J Surg* 2006;93:885–90.
- [76] al-Samarrai AY, Mofiti AB, Crankson SJ, Jawad A, Haque K, al-Meshari A. A review of a Plastibell device in neonatal circumcision in 2,000 instances. *Surg Gynecol Obstet* 1988;167:341–3.
- [77] IA J. Circumcision in babies and children with plastibell technique: an easy procedure with minimal complications – experience of 316 cases. *Pakistan J Med Sci* 2004;20:175–80.
- [78] Weiss HA, Larke N, Halperin D, Schenker I. Complications of circumcision in male neonates, infants and children: a systematic review. *BMC Urol* 2010;10:2.
- [80] Griffiths DM, Atwell JD, Freeman NV. A prospective survey of the indications and morbidity of circumcision in children. *Eur Urol* 1985;11:184–7.
- [81] Sørensen SM, Sørensen MR. Circumcision with the Plastibell device. A long-term follow-up. *Int Urol Nephrol* 1988;20:159–66.
- [82] Subramaniam R, Jacobsen AS. Sutureless circumcision: a prospective randomized controlled study. *Pediatr Surg Int* 2004;20:783–5.
- [83] Harel L, Straussberger R, Jackson S, Amir J, Tiqwa P. Influence of circumcision technique on frequency of urinary tract infections in neonates. *Pediatr Infect Dis J* 2002;21:879–80.
- [84] Prais D, Shoov-Furman R, Amir J. Is ritual circumcision a risk factor for neonatal urinary tract infections? *Arch Dis Child* 2009;94:191–4.
- [85] Ben Chaim J, Livne PM, Binyamini J, Hardak B, Ben-Meir D, Mor Y. Complications of circumcision in Israel: a one year multicenter survey. *Isr Med Assoc J* 2005;7:368–70.
- [86] Yegane R-A, Kheirollahi A-R, Salehi N-A, Bashashati M, Khoshdel J-A, Ahmadi M. Late complications of circumcision in Iran. *Pediatr Surg Int* 2006;22:442–5.
- [87] Morris BJ, Wiswell TE. Circumcision and lifetime risk of urinary tract infection: a systematic review and meta-analysis. *J Urol* 2013;189:2118–24.
- [88] Osuigwe A, Ikechebelu J, Okafor P. Circumcision-related complications in the male: experience amongst the Igbo's of Southeast Nigeria. *African J Urol* 2005;10:246–51.
- [89] Crowley IP, Kesner KM. Ritual circumcision (Umkhwetha) amongst the Xhosa of the Ciskei. *Br J Urol* 1990;66:318–21.
- [90] Wilcken A, Keil T, Dick B. Traditional male circumcision in eastern and southern Africa: a systematic review of prevalence and complications. *Bull World Health Organ* 2010;88:907–14.
- [91] Cao D, Liu L, Hu Y, Wang J, Yuan J, Dong Q, et al. A systematic review and meta-analysis of circumcision with Shang Ring vs conventional circumcision. *Urology* 2015;85:799–804.
- [92] Morris BJ, Bailis SA, Wiswell TE. Circumcision rates in the United States: rising or falling? What effect might the new affirmative pediatric policy statement have? *Mayo Clin Proc* 2014;89:677–86.